Triple-negative breast cancer cell lines treated with mebedazole (an FDA-approved anti-parasitic).

The main purpose of this project is to identify gene expression changes between treated triple negative breast cancer cells (w/ MBZ) vs. non-treated cells (w/o MBZ). We have submitted two different cell ilnes, and those overlapping pathways will be important to elucidate the mechansim of MBZ. Cell Lines = SM or MD Drug treatment = 0M or 1M Overall design: In order to determine the overall effect of MBZ treatment in triple-negative breast cancer (TNBC), TNBC cell lines (MDA-MB-231 and SUM159) were treated either with 1 uM MBZ or DMSO vehicle control for 72 hours and RNA was extracted.